Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Expert Consensus on Ivabradine-based Therapy for Heart Rate Management in Chronic Coronary Syndrome and Heart Failure with Reduced Ejection Fraction in India

Author(s): J.C. Mohan, I. Sathyamurthy, Monotosh Panja, Rajeev Agarwala, C.K. Ponde, A. Sreenivas Kumar, Bijay Kumar Mahala, Vivek Kolapkar*, R.V. Lokesh Kumar and Kamlesh Patel

Volume 19, Issue 5, 2023

Published on: 25 May, 2023

Article ID: e200323214735 Pages: 10

DOI: 10.2174/1573403X19666230320105623

Price: $65

Abstract

Heart rate is an important indicator of health and disease and the modulation of heart rate can help to improve cardiovascular outcomes. Besides β-blockers, Ivabradine is a wellestablished heart rate modulating drug that reduces heart rate without any hemodynamic effects. This consensus document was developed with the help of expert opinions from cardiologists across India on effective heart rate management in routine clinical practice and choosing an appropriate Ivabradine-based therapy considering the available scientific data and guideline recommendations. Based on the discussion during the meetings, increased heart rate was recognized as a significant predictor of adverse cardiovascular outcomes among patients with chronic coronary syndromes and heart failure with reduced ejection fraction making heart rate modulation important in these subsets. Ivabradine is indicated in the management of chronic coronary syndromes and heart failure with reduced ejection fraction for patients in whom heart rate targets cannot be achieved despite guideline-directed β-blocker dosing or having contraindication/intolerance to β-blockers. A prolonged release once-daily dosage of Ivabradine can be considered in patients already stabilized on Ivabradine twice-daily. Ivabradine/β-blocker fixed-dose combination can also be considered to reduce pill burden. Two consensus algorithms have been developed for further guidance on the appropriate usage of Ivabradine-based therapies. Ivabradine and β-blockers can provide more pronounced clinical improvement in most chronic coronary syndromes and heart failure with reduced ejection fraction patients with a fixed-dose combination providing an opportunity to improve adherence.

Graphical Abstract

[1]
Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J Am Coll Cardiol 2020; 76(25): 2982-3021.
[http://dx.doi.org/10.1016/j.jacc.2020.11.010] [PMID: 33309175]
[2]
Sreeniwas KA, Sinha N. Cardiovascular disease in India: A 360 degree overview. Med J Armed Forces India 2020; 76(1): 1-3.
[http://dx.doi.org/10.1016/j.mjafi.2019.12.005] [PMID: 32020960]
[3]
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41(3): 407-77.
[http://dx.doi.org/10.1093/eurheartj/ehz425] [PMID: 31504439]
[4]
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020; 22(8): 1342-56.
[http://dx.doi.org/10.1002/ejhf.1858] [PMID: 32483830]
[5]
Harikrishnan S, Jeemon P, Ganapathi S, et al. Five-year mortality and readmission rates in patients with heart failure in India: Results from the Trivandrum heart failure registry. Int J Cardiol 2021; 326: 139-43.
[http://dx.doi.org/10.1016/j.ijcard.2020.10.012] [PMID: 33049297]
[6]
Jensen MT. Resting heart rate and relation to disease and longevity: past, present and future. Scand J Clin Lab Invest 2019; 79(1-2): 108-16.
[http://dx.doi.org/10.1080/00365513.2019.1566567] [PMID: 30761923]
[7]
Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension 1999; 33(1): 44-52.
[http://dx.doi.org/10.1161/01.HYP.33.1.44] [PMID: 9931080]
[8]
Jouven X, Zureik M, Desnos M, Guérot C, Ducimetière P. Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res 2001; 50(2): 373-8.
[http://dx.doi.org/10.1016/S0008-6363(01)00230-9] [PMID: 11334841]
[9]
Hamill V, Ford I, Fox K, et al. Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction. Am J Med 2015; 128(10): 1102-1108.e6.
[http://dx.doi.org/10.1016/j.amjmed.2015.04.042] [PMID: 26044936]
[10]
Kaul U, Wander GS, Sinha N, et al. Self-blood pressure measurement as compared to office blood pressure measurement in a large Indian population; the India Heart Study. J Hypertens 2020; 38(7): 1262-70.
[http://dx.doi.org/10.1097/HJH.0000000000002410] [PMID: 32195821]
[11]
Rao D, Balagopalan JP, Sharma A, Chauhan VC, Jhala D. BEAT survey: A cross-sectional study of resting heart rate in young (18-55 Year) hypertensive patients. J Assoc Physicians India 2015; 63(5): 14-7.
[PMID: 26591139]
[12]
Sengupta SP, Burkule N, Bansal M, et al. Normative values of cardiac chamber dimensions and global longitudinal strain in Indians: The Indian normative data of echocardiography analyzed (INDEA) study. Int J Cardiovasc Imaging 2021; 37(3): 871-80.
[http://dx.doi.org/10.1007/s10554-020-02060-8] [PMID: 33047178]
[13]
Padmanabhan TNC, Dani S, Chopra VK, Guha S, Vasnawala H, Ammar R. Prevalence of sympathetic overactivity in hypertensive patients – A pan India, non-interventional, cross sectional study. Indian Heart J 2014; 66(6): 686-90.
[http://dx.doi.org/10.1016/j.ihj.2014.10.421] [PMID: 25634406]
[14]
Aune D, Sen A, ó’Hartaigh B, et al. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality – A systematic review and dose–response meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis 2017; 27(6): 504-17.
[http://dx.doi.org/10.1016/j.numecd.2017.04.004] [PMID: 28552551]
[15]
Daly CA, Clemens F, Lopez Sendon JL, et al. Inadequate control of heart rate in patients with stable angina: Results from the European Heart Survey. Postgrad Med J 2010; 86(1014): 212-7.
[http://dx.doi.org/10.1136/pgmj.2009.084384] [PMID: 20354044]
[16]
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial. Lancet 2008; 372(9641): 817-21.
[http://dx.doi.org/10.1016/S0140-6736(08)61171-X] [PMID: 18757091]
[17]
Kurgansky KE, Schubert P, Parker R, et al. Association of pulse rate with outcomes in heart failure with reduced ejection fraction: A retrospective cohort study. BMC Cardiovasc Disord 2020; 20(1): 92.
[http://dx.doi.org/10.1186/s12872-020-01384-6] [PMID: 32101141]
[18]
Habal MV, Liu PP, Austin PC, et al. Association of heart rate at hospital discharge with mortality and hospitalizations in patients with heart failure. Circ Heart Fail 2014; 7(1): 12-20.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000429] [PMID: 24297690]
[19]
Ferrari R, Fox K. Heart rate reduction in coronary artery disease and heart failure. Nat Rev Cardiol 2016; 13(8): 493-501.
[http://dx.doi.org/10.1038/nrcardio.2016.84] [PMID: 27226153]
[20]
Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of ivabradine. J Am Coll Cardiol 2017; 70(14): 1777-84.
[http://dx.doi.org/10.1016/j.jacc.2017.08.038] [PMID: 28958335]
[21]
Tse S, Mazzola N. Ivabradine (Corlanor) for heart failure: The first selective and specific I f Inhibitor. P&T 2015; 40(12): 810-4.
[PMID: 26681903]
[22]
Mullasari A, Mahajan A, Chanana BB, et al. Efficacy and safety of ivabradine once-daily prolonged-release versus twice-daily immediate-release formulation in patients with stable chronic heart failure with systolic dysfunction: A randomized, double-blind, phase 3 non-inferiority (PROFICIENT) study. Cardiol Ther 2020; 9(2): 505-21.
[http://dx.doi.org/10.1007/s40119-020-00200-8] [PMID: 33006062]
[23]
Kaski JC, Gloekler S, Ferrari R, et al. Role of ivabradine in management of stable angina in patients with different clinical profiles. Open Heart 2018; 5(1): e000725.
[http://dx.doi.org/10.1136/openhrt-2017-000725] [PMID: 29632676]
[24]
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: A subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009; 30(19): 2337-45.
[http://dx.doi.org/10.1093/eurheartj/ehp358] [PMID: 19720635]
[25]
Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371(12): 1091-9.
[http://dx.doi.org/10.1056/NEJMoa1406430] [PMID: 25176136]
[26]
Giavarini A, de Silva R. The role of ivabradine in the management of angina pectoris. Cardiovasc Drugs Ther 2016; 30(4): 407-17.
[http://dx.doi.org/10.1007/s10557-016-6678-x] [PMID: 27475447]
[27]
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599-726.
[http://dx.doi.org/10.1093/eurheartj/ehab368] [PMID: 34447992]
[28]
Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010; 376(9744): 875-85.
[http://dx.doi.org/10.1016/S0140-6736(10)61198-1] [PMID: 20801500]
[29]
Swedberg K, Komajda M, Böhm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: Findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012; 59(22): 1938-45.
[http://dx.doi.org/10.1016/j.jacc.2012.01.020] [PMID: 22617188]
[30]
Borer JS, Böhm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 2012; 33(22): 2813-20.
[http://dx.doi.org/10.1093/eurheartj/ehs259] [PMID: 22927555]
[31]
Komajda M, Tavazzi L, Swedberg K, et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: A post-hoc analysis of SHIFT. Eur J Heart Fail 2016; 18(9): 1182-9.
[http://dx.doi.org/10.1002/ejhf.582] [PMID: 27210035]
[32]
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation 2022; 145(18): e895-e1032.
[http://dx.doi.org/10.1161/CIR.0000000000001063] [PMID: 35363499]
[33]
Maddox TM, Januzzi JL Jr, Allen LA, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol 2021; 77(6): 772-810.
[http://dx.doi.org/10.1016/j.jacc.2020.11.022] [PMID: 33446410]
[34]
Steg PG, Ferrari R, Ford I, et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One 2012; 7(5): e36284.
[http://dx.doi.org/10.1371/journal.pone.0036284] [PMID: 22570699]
[35]
Kau LU, Natrajan S, Dalal J, Saran RK. Prevalence and control of cardiovascular risk factors in stable coronary artery outpatients in India compared with the rest of the world: An analysis from international CLARIFY registry. Indian Heart J 2017; 69(4): 447-52.
[http://dx.doi.org/10.1016/j.ihj.2017.05.014] [PMID: 28822509]
[36]
Lam CSP, Teng THK, Tay WT, et al. Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. Eur Heart J 2016; 37(41): 3141-53.
[http://dx.doi.org/10.1093/eurheartj/ehw331] [PMID: 27502121]
[37]
Rao MS, Mandal S. Epidemiologic surveillance on quality of life in patients with systolic heart failure after treatment with the selective heart rate inhibitor ivabradine. J Pract Cardiovasc Sci 2017; 3(2): 100-2.
[http://dx.doi.org/10.4103/jpcs.jpcs_8_17]
[38]
Bhatt AS, DeVore AD, DeWald TA, Swedberg K, Mentz RJ. Achieving a maximally tolerated β-blocker dose in heart failure patients. J Am Coll Cardiol 2017; 69(20): 2542-50.
[http://dx.doi.org/10.1016/j.jacc.2017.03.563] [PMID: 28521892]
[39]
Ibrahim NE, Gaggin HK, Turchin A, et al. Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. Eur Heart J Cardiovasc Pharmacother 2019; 5(1): 3-11.
[http://dx.doi.org/10.1093/ehjcvp/pvy011] [PMID: 29490032]
[40]
DeVore AD, Mi X, Mentz RJ, et al. Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. Am Heart J 2016; 173: 172-8.
[http://dx.doi.org/10.1016/j.ahj.2015.10.026] [PMID: 26920611]
[41]
Eriksen-Volnes T, Westheim A, Gullestad L, Slind EK, Grundtvig M. β-blocker doses and heart rate in patients with heart failure: Results from the national norwegian heart failure registry Biomed Hub 2020; 5(1): 1-10.
[http://dx.doi.org/10.1159/000505474] [PMID: 32775329]
[42]
Goldberger JJ, Subačius H, Marroquin OC, et al. One-year landmark analysis of the effect of beta-blocker dose on survival after acute myocardial infarction. J Am Heart Assoc 2021; 10(14): e019017.
[http://dx.doi.org/10.1161/JAHA.120.019017] [PMID: 34227397]
[43]
Cullington D, Goode KM, Clark AL, Cleland JGF. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: Which is the better target? Eur J Heart Fail 2012; 14(7): 737-47.
[http://dx.doi.org/10.1093/eurjhf/hfs060] [PMID: 22622001]
[44]
Webster R, Murphy A, Bygrave H, Ansbro É, Grobbee DE, Perel P. Implementing fixed dose combination medications for the prevention and control of cardiovascular diseases. Glob Heart 2020; 15(1): 57.
[http://dx.doi.org/10.5334/gh.860] [PMID: 32923350]
[45]
Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J 2018; 39(40): 3654-61.
[http://dx.doi.org/10.1093/eurheartj/ehy420] [PMID: 30060044]
[46]
Katsi V, Skalis G, Kallistratos MS, et al. Ivabradine and metoprolol in fixed dose combination: When, why and how to use it. Pharmacol Res 2019; 146: 104279.
[http://dx.doi.org/10.1016/j.phrs.2019.104279] [PMID: 31108185]
[47]
Volterrani M, Iellamo F. Complementary and synergic role of combined beta-blockers and ivabradine in patients with chronic heart failure and depressed systolic function: A new therapeutic option? Card Fail Rev 2016; 2(2): 130-6.
[http://dx.doi.org/10.15420/cfr.2016:12:1] [PMID: 28785467]
[48]
Glezer M, Vasyuk Y, Karpov Y. Efficacy of ivabradine in combination with beta-blockers versus uptitration of beta-blockers in patients with stable angina (CONTROL-2 Study). Adv Ther 2018; 35(3): 341-52.
[http://dx.doi.org/10.1007/s12325-018-0681-5] [PMID: 29508153]
[49]
Werdan K, Ebelt H, Nuding S, Höpfner F, Hack G, Müller-Werdan U. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: Results from the ADDITIONS study. Clin Res Cardiol 2012; 101(5): 365-73.
[http://dx.doi.org/10.1007/s00392-011-0402-4] [PMID: 22231643]
[50]
Divchev D, Stöckl G. Treatment of stable angina with a new fixed-dose combination of ivabradine and metoprolol: Effectiveness and tolerability in routine clinical practice. Cardiol Ther 2017; 6(2): 239-49.
[http://dx.doi.org/10.1007/s40119-017-0099-1] [PMID: 29116618]
[51]
Divchev D, Stöckl G. Effectiveness and impact on adherence of a new fixed-dose combination of ivabradine and metoprolol in a wide range of stable angina patients in real-life practice. Cardiol Ther 2019; 8(2): 317-28.
[http://dx.doi.org/10.1007/s40119-019-00145-7] [PMID: 31410662]
[52]
Tardif JC, Ponikowski P, Kahan T. Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol 2013; 168(2): 789-94.
[http://dx.doi.org/10.1016/j.ijcard.2012.10.011] [PMID: 23138014]
[53]
Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther 2011; 25(6): 531-7.
[http://dx.doi.org/10.1007/s10557-011-6327-3] [PMID: 21830063]
[54]
Bocchi EA, Böhm M, Borer JS, et al. Effect of combining ivabradine and β-blockers: Focus on the use of carvedilol in the shift population. Cardiology 2015; 131(4): 218-24.
[http://dx.doi.org/10.1159/000380812] [PMID: 25968495]
[55]
Hidalgo FJ, Carrasco F, Castillo JC, et al. Early therapy with beta blockers plus ivabradine versus beta blockers alone in patients hospitalised with heart failure and reduced ejection fraction (ETHICAHF Study): Results at one-year follow-up. Int J Clin Cardiol 2017; 4: 093.
[http://dx.doi.org/10.23937/2378-2951/1410093]
[56]
Lopatin YM, Cowie MR, Grebennikova AA, et al. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: insights from the optimize heart failure care program. Int J Cardiol 2018; 260: 113-7.
[http://dx.doi.org/10.1016/j.ijcard.2017.12.093] [PMID: 29622423]
[57]
Bagriy AE, Schukina EV, Samoilova OV, et al. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study. Adv Ther 2015; 32(2): 108-19.
[http://dx.doi.org/10.1007/s12325-015-0185-5] [PMID: 25700807]
[58]
Volterrani M, Cice G, Caminiti G, et al. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). Int J Cardiol 2011; 151(2): 218-24.
[http://dx.doi.org/10.1016/j.ijcard.2011.06.098] [PMID: 21764469]
[59]
Zugck C, Martinka P, Stöckl G. Ivabradine treatment in a chronic heart failure patient cohort: Smptom reduction and improvement in quality of life in clinical practice. Adv Ther 2014; 31(9): 961-74.
[http://dx.doi.org/10.1007/s12325-014-0147-3] [PMID: 25160945]
[60]
Bhatt AS, Choudhry NK. Evidence-based prescribing and polypharmacy for patients with heart failure. Ann Intern Med 2021; 174(8): 1165-6.
[http://dx.doi.org/10.7326/M21-1427] [PMID: 34181442]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy